Geron Corporation (NASDAQ:GERN) Q3 2023 Earnings Conference Call November 2, 2023 9:00 AM ET
Corporate Participants
Aron Feingold - Vice President, Investor Relations and Corporate Communications
John Scarlett - Chairman, President and Chief Executive Officer
Faye Feller - Executive Vice President and Chief Medical Officer
Anil Kapur - Executive Vice President, Corporate Strategy and Chief Commercial Officer
Michelle Robertson - Executive Vice President and Chief Financial Officer
Conference Call Participants
Tuuli Tsogtbaatar - Stifel
Craig Miller - Goldman Sachs
Kalpit Patel - B. Riley
Ethan Markowski - Needham & Company
Joel Beatty - Baird
Operator
Good morning. My name is Audrey, and I will be your conference operator today. At this time, I would like to welcome everyone to the Geron Corporation Third Quarter 2023 Earnings Conference Call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers remarks' there will be a question-and-answer session. [Operator Instructions].
At this time, I would like to turn the conference over to Aron Feingold, VP of Investor Relations and Corporate Communications. Please go ahead.
Aron Feingold
Good morning, everyone. Welcome to the Geron Corporation third quarter 2023 earnings conference call. I'm Aron Feingold, Geron's Vice President of Investor Relations and Corporate Communications.
I'm joined today by several members of Geron's management team. Dr. John Scarlett, Chairman and Chief Executive Officer; Michelle Robertson, Executive Vice President and Chief Financial Officer; Dr. Faye Feller, Executive Vice President and Chief Medical Officer; Anil Kapur, Executive Vice President of Corporate Strategy and Chief Commercial Officer; and Dr Andrew Grethlein, Executive Vice President and Chief Operating Officer.
Before we begin, please note that, during the course of this presentation and question-and-answer session, we will be making forward-looking statements regarding future events, performance, plans, expectations and other projections including those relating to the therapeutic potential and potential regulatory approval of imetelstat, anticipated clinical and commercial events and related time lines, the sufficiency of Geron's financial resources and other statements that are not historical facts. Actual events or results could differ materially. Therefore, I refer you to the discussion under the heading Risk Factors in Geron's quarterly report on Form 10-Q for the quarter ended September 30, 2023, which identifies important factors that could cause actual results to differ materially from those contained in the forward-looking statements. Geron undertakes no duty or obligation to update our forward-looking statements.
With that, I will turn the call over to Chip. Chip?